| AASLD

Practice Guidelines

Read more about Practice Guidelines

AASLD develops evidence-based practice guidelines, practice guidances, and patient guidances to share recommended approaches to the diagnostic, therapeutic, and preventive aspects of care.

Nonalcoholic Fatty Liver Disease Patients Have Higher Rates of All Non-Liver-Related Cancers

Read more about Nonalcoholic Fatty Liver Disease Patients Have Higher Rates of All Non-Liver-Related Cancers

Media Contact: Caroline Laurin
Phone: (703) 299-9766
Onsite phone: (415)-978-3601
Email: media@aasld.org

San Francisco –...

New Machine Learning-Based Model More Accurately Predicts Liver Transplant Waitlist Mortality

Read more about New Machine Learning-Based Model More Accurately Predicts Liver Transplant Waitlist Mortality

Media Contact: Caroline Laurin
Phone: (703) 299-9766
Email: media@aasld.org

Alexandria, VA – Data from a new study presented...

Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Read more about Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Benjamin L. Shneider, Catherine A. Spino, Binita M. Kamath, John C. Magee, Rosalinda V. Ignacio, Suiyuan Huang, Simon P. Horslen, Jean P. Molleston, Alexander G. Miethke, Rohit Kohli, Daniel H. Leung, M. Kyle Jensen, Kathleen M. Loomes, Saul J. Karpen, Cara Mack, Philip Rosenthal, Robert H. Squires, Alastair Baker, Sanjay Rajwal, Deirdre Kelly, Ronald J. Sokol, Richard J. Thompson, for ChiLDReN and UK IMAGO/IMAGINE Investigators – 6 June 2022 – There is growing interest in, but limited data about, intestinal bile acid transport inhibitors as treatment for cholestatic liver disease.